AtriCure CTO Sells 3,657 Shares; Keeps $7.9M Stake

For medical device executives, insider sales are often less about confidence and more about pre-scheduled diversification. AtriCure's CTO Salvatore Privitera offloaded 3,657 shares on September 8 under a Rule 10b5-1 plan established months earlier, retaining roughly 147,000 shares. The real question for healthcare leaders is not the sale itself, but whether hospitals and surgical centers continue adopting AtriCure's Isolator Synergy Clamps and MAX Pen.

AtriCure Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on September 8, 2026, at a weighted average price of $55, according to a recent SEC Form 4 filing. The transaction generated approximately $201,135 and was executed under a Rule 10b5-1 trading plan adopted in February 2026. Because the plan was established months before the sale, the timing of the transaction is largely divorced from any material nonpublic information Privitera may have held as a senior executive, making this a relatively weak bearish signal. After the sale, Privitera retains approximately 147,000 shares, a stake worth about $7.9 million based on the September 8 close of $53.73. This retained equity positions him to benefit from future appreciation, which weighs against reading the sale as a loss of confidence.

“

After the sale, Privitera retains approximately 147,000 shares, a stake worth about $7.9 million based on the September 8 close of $53.73.

AtriCure generated trailing twelve-month revenue of $569.6 million and net income of $10.6 million at the time of the filing, underscoring a company that has scaled its top line but operates with thin profitability. The stock closed at $53.73 on September 8, 2026, a 49% increase over the preceding 12 months. That rally likely encouraged some executive profit-taking even under prearranged plans. With sales of specialized devices such as Isolator Synergy Clamps and MAX Pen to hospitals and surgical centers, AtriCure occupies a niche in cardiac arrhythmia treatment and nerve ablation. Demand for minimally invasive and surgical ablation has been supported by an aging population and rising atrial fibrillation prevalence, although hospital capital spending cycles and competitive dynamics in electrophysiology remain important constraints.

For healthcare stakeholders, the CTO sale is unlikely to signal operational trouble. Insider selling under 10b5-1 plans is routine across medtech. The more meaningful variables are product adoption, regulatory clearances, and clinical outcomes. Still, the juxtaposition of modest net income against a strong valuation gain suggests the stock may be pricing in continued growth that has yet to materialize fully in earnings.